Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CB | P42338 | 8/20 | 0.39 |
| ▸ | PIK3CA | P42336 | 7/20 | 0.39 |
| ▸ | PIK3CD | O00329 | 4/20 | 0.39 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.39 |
| ▸ | PIK3CG | P48736 | 1/20 | 0.39 |
| ▸ | CNR2 | P34972 | 2/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | ATR | Q13535 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15878892 | 0.78 | PIK3CB (0.46) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL15473880 | 0.77 | PIK3CD (0.38) | PIK3CDKDM4EATR | |
| SCHEMBL15471366 | 0.76 | S1PR1 (0.41) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL15878553 | 0.75 | PIK3CB (0.44) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL15878672 | 0.75 | PIK3CB (0.44) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL16997495 | 0.71 | CNR2 (0.36) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL15877882 | 0.70 | PIK3CB (0.42) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL15877883 | 0.70 | PIK3CB (0.42) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL15920612 | 0.70 | PIK3CB (0.42) | PIK3CBPIK3CAPIK3CDPIK3R1PIK3CG | |
| SCHEMBL16997502 | 0.69 | KDM4E (0.47) | CNR2KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170226131-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | EXELIXIS, INC. (US) | 2017-08-10 | — | — | US | disclosed |
| US-9670212-B2 | Inhibitors of PI3K-delta and methods of their use and manufacture | EXELIXIS, INC. (US) | 2017-06-06 | — | — | US | disclosed |
| US-9657008-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2017-05-23 | — | — | US | disclosed |
| US-9657008-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2017-05-23 | — | — | US | disclosed |
| US-9657008-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2017-05-23 | — | — | US | disclosed |
| EP-2948447-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2016-09-21 | — | — | EP | disclosed |
| EP-2948447-B1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2016-09-21 | — | — | EP | disclosed |
| US-20160137634-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-05-19 | — | — | US | disclosed |
| US-20160137634-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-05-19 | — | — | US | disclosed |
| US-20160137634-A1 | Chemical Compounds | ASTRAZENECA AB (SE) | 2016-05-19 | — | — | US | disclosed |
| EP-2948447-A1 | CHEMICAL COMPOUNDS | Astrazeneca AB (SE) | 2015-12-02 | — | — | EP | disclosed |
| US-9156831-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-10-13 | — | — | US | disclosed |
| US-9156831-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-10-13 | — | — | US | disclosed |
| US-9156831-B2 | Chemical compounds | ASTRAZENECA AB (SE) | 2015-10-13 | — | — | US | disclosed |
| WO-2014114928-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014114928-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-07-31 | — | — | WO | disclosed |
| US-20140206700-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-07-24 | — | — | US | disclosed |
| US-20140206700-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-07-24 | — | — | US | disclosed |
| US-20140206700-A1 | CHEMICAL COMPOUNDS | ASTRAZENECA AB (SE) | 2014-07-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170226131-A1 | Inhibitors of PI3K-Delta and Methods of Their Use and Manufacture | PIK3CD, PIK3CA, PIK3R5 | PIK3CB 5/4885PIK3CA 2/4885PIK3CD 1/4885 |
| US-20140206700-A1 | CHEMICAL COMPOUNDS | MKI67, CCNI, TP53 | PIK3CB 1962/4885PIK3CA 1124/4885PIK3CD 2304/4885 |
| US-20160137634-A1 | Chemical Compounds | MKI67, CCNI, TP53 | PIK3CB 1962/4885PIK3CA 1124/4885PIK3CD 2304/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.